Sep
27
2018

Biotech Briefing: Forge Therapeutics Gets Info from Achaogen to Develop New Antibiotics

The Hatch

What started out as a “scientific symposium” on stem cells has grown into a three-day conference with talks, corporate presentations, and a partnering forum for cell and gene therapies. The Cell and Gene Meeting on the Mesa will bring together over 1,000 attendees who will take part in more than 1,450 one-on-one meetings to support partnering.

Sep
21
2018

Recent Progress in European Advanced Therapy Medicinal Products and Beyond

Frontiers in Bioengineering and Biotechnology

Cell- and gene-based therapies form one of the pillars of regenerative medicine. They have the potential to transform quality of life and improve the health status of patients with genetic and cellular defects, including genetic diseases, neurodegenerative diseases and tissue malignancies, amongst others. Despite numerous challenges, in the last decade, tremendous unified efforts by research and clinical scientists in academic, translational and industry settings have resulted in tangible outcomes in the form of many marketing authorizations and approved commercial firsts

Sep
20
2018

Bridging The Public Knowledge Gap Around Cell And Gene Medicine

Cell And Gene

Cell and gene therapies hold the potential to transform medicine; however, if patients are to gain access to these therapies, we must increase public awareness and understanding of how these therapies can benefit them. According to a review of recent research studies that measured U.S. public opinion related to gene medicine,1 the public is not yet aware of gene medicine; is unfamiliar with the terms being used to describe the topic; and, when faced with multiple therapeutic options, is worried about making informed decisions.

Aug
21
2018

Clinical Trial Boom Boosts Cryoport Revenues 59% in Q2 2018

Outsourcing Pharma

There is a record number of clinical trials driven by rapid growth in regenerative medicine – a space that will continue to grow and outpace the pharmaceutical industry.

Aug
16
2018

Regenerative Medicine: Finding Ways for the Body to Heal Itself

William Blair

One of the most exciting areas in healthcare today is regenerative medicine. This simple term encompasses a rapidly expanding revolution in medical research, which in its application by physicians is allowing the body to heal itself in ways never before seen.

Aug
16
2018

A Sit Down With ARM's CEO, Janet Lambert

Cell and Gene

Janet Lambert joined the Alliance for Regenerative Medicine (ARM) as CEO just over a year ago. And what a year it’s been. Recently, I had the opportunity to talk to Lambert about her first year as CEO, what ARM is doing in cell and gene therapies from clinical and commercialization points of view, as well as its areas of short-term focus. Here’s what she had to say.

Aug
15
2018

Alnylam to Offer Value-Based Contracts for $450,000 Rare Disease Drug

American Journal of Managed Care

The Alliance for Regenerative Medicine’s Foundation for Cell and Gene Medicine, an organization that focuses on issues that face regenerative and advanced therapies, recently released a report, prepared by IQVIA, that finds that outcomes-based contracts for products like tisagenlecleucel (Kymriah) and voretigene neparvovec-rzyl (Luxturna) have helped to overcome payers’ skepticism about high-cost drugs.

Aug
13
2018

New Drugs so Pricey They Need New Payment Plans

Politico Prescription Pulse

So far, regenerative medicine and other advanced therapies — including CAR-T and stem cell therapies — haven’t met market expectations because of difficulties determining their value, according to a recent analysis from the ARM Foundation for Cell and Gene Medicine. Innovative payment models have helped overcome payer uncertainty about high upfront costs, according to the foundation’s analysis.